NAD+ and GLP-1: The Over-40 Longevity Stack Men Are Asking About

NAD+ levels drop roughly 50% by age 50. GLP-1s are emerging as the first drug class to target multiple hallmarks of aging simultaneously. Here's what the research actually supports — and what's still speculation.

Published May 1, 2026 · Last verified May 1, 2026

If you spend any time in men's health or longevity circles, you've probably heard the pitch: combine NAD+ therapy with a GLP-1 medication and you've got a "longevity stack" that attacks aging from multiple angles. The idea is appealing. NAD+ restores cellular energy production. GLP-1s reduce inflammation and metabolic dysfunction. Together, they should address the root causes of why men over 40 start feeling slower, heavier, and less sharp.

But how much of this is backed by clinical evidence, and how much is biohacker speculation riding on legitimate but early science? Let's break it down.

What NAD+ Actually Does (and Doesn't Do)

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every cell. It's essential for mitochondrial energy production, DNA repair, and the activation of sirtuins — a family of proteins linked to cellular aging and metabolic regulation. Without adequate NAD+, your mitochondria can't efficiently convert food into energy. DNA damage accumulates faster. Inflammatory pathways get louder.

Human studies confirm that NAD+ precursors like NR (nicotinamide riboside) reliably raise circulating NAD+ levels and support mitochondrial function, neuroprotection, and anti-inflammatory pathways. Clinical trials are ongoing in heart failure, long COVID, multiple sclerosis, and cancer. However, the research is more nuanced than supplement companies suggest.

A key limitation: raising NAD+ in blood doesn't guarantee it reaches the tissues where you need it most. Researchers are increasingly focused not just on boosting NAD+ levels but on inhibiting the enzymes (CD38, PARPs, NAMPT) that deplete it. The field is evolving from "take more NAD+" to "stop leaking the NAD+ you have."

Why GLP-1s Are Being Called "Longevity Drugs"

A November 2025 article in Nature Biotechnology asked the question directly: "Are GLP-1s the first longevity drugs?" The answer was cautiously optimistic. GLP-1 receptor agonists have more human data supporting multi-organ protective effects than any previous anti-aging candidate — including metformin, rapamycin, NAD+ precursors, and senolytics.

The pivotal data point: the SELECT trial demonstrated a 20% reduction in major cardiovascular events with semaglutide in people with obesity but without diabetes. About a third of that cardiovascular benefit was independent of weight loss entirely — suggesting something mechanistically deeper was happening.

GLP-1 receptors are distributed across virtually every organ system — heart, brain, kidneys, liver — and activating them triggers anti-inflammatory and cellular repair cascades that directly counteract biological aging processes. These include reducing oxidative stress, protecting against cellular senescence, and dampening chronic low-grade inflammation (sometimes called "inflammaging").

The NAD+ + GLP-1 Theory: Where They Overlap

The rationale for combining NAD+ and GLP-1 therapy is mechanistically logical, even if clinical trial data for the specific combination doesn't exist yet. Both interventions target overlapping aging pathways:

The theoretical argument is that NAD+ addresses the energy and repair side of aging (keep mitochondria running, keep DNA intact), while GLP-1s address the inflammatory and metabolic side (reduce visceral fat, calm systemic inflammation, protect organs). They're complementary, not redundant.

The Men-Specific Angle: Testosterone and Leydig Cells

This is where the story gets particularly interesting for men over 40. Leydig cells — the cells in the testes responsible for producing testosterone — are highly dependent on mitochondrial function. When NAD+ levels decline, Leydig cell efficiency drops, which may contribute to the testosterone decline that accelerates after age 40.

Meanwhile, GLP-1 medications are showing independent benefits for testosterone. A 2025 electronic health record analysis of 110 men on GLP-1 therapy for 18 months found that the proportion with normal total and free testosterone went from 53% to 77%, with average total testosterone rising by 18%. A 2025 Italian pilot study found that tirzepatide produced larger increases in both free and total testosterone than transdermal TRT over 8 weeks.

The mechanism is straightforward: excess visceral fat converts testosterone to estrogen via aromatase. GLP-1 medications reduce visceral fat, which reduces aromatization and lets testosterone levels recover naturally. NAD+ may support this by keeping Leydig cells metabolically healthy enough to respond to that improved hormonal environment.

How Men Over 40 Are Approaching This

Despite the lack of combination-specific trials, many men are pragmatically layering these interventions. The typical approach looks something like this:

Foundation layer: A GLP-1 medication (semaglutide or tirzepatide) to address weight, metabolic health, and systemic inflammation. This has the strongest evidence base and the most measurable outcomes.

Cellular support layer: NAD+ therapy — either through at-home injections (bypassing digestive degradation) or high-dose NR/NMN supplementation — to support mitochondrial function and DNA repair.

Monitoring layer: Regular bloodwork tracking testosterone (total and free), inflammatory markers (hsCRP), fasting insulin, HbA1c, and ideally NAD+ metabolites if available through a provider.

The critical point is that the GLP-1 medication has the most robust evidence and the most reliable outcomes. NAD+ therapy is a reasonable addition based on mechanistic plausibility, but it shouldn't be treated as a substitute for metabolic health optimization through weight management.

Delivery Method Matters for NAD+

Oral NAD+ supplements (NR, NMN) face significant bioavailability challenges. NAD+ itself is broken down in the gut before it can reach cells. Precursors like NR perform better but still face limitations in how efficiently they raise tissue-level NAD+.

This is why injectable NAD+ — administered subcutaneously at home — has become the preferred delivery method among telehealth longevity providers. The medication bypasses the digestive system entirely, allowing for more consistent absorption. Several telehealth platforms now offer physician-supervised NAD+ injection programs with online intake, licensed provider review, and home delivery.

Compounded medications are not FDA-approved. NAD+ injections are not FDA-approved for treating any specific condition. Consult your provider.

What the Evidence Supports vs. What's Speculative

The Bottom Line

The NAD+ and GLP-1 combination makes biological sense. Both target overlapping but distinct aging mechanisms. GLP-1 medications have the strongest evidence base of any anti-aging intervention available today. NAD+ therapy has solid mechanistic support and good safety data, but fewer hard clinical endpoints.

If you're a man over 40 considering this approach, start with the intervention that has the most evidence and the most measurable outcomes: a GLP-1 medication under physician supervision for metabolic optimization. If you're already on that foundation and want to add NAD+ therapy, look for telehealth providers offering physician-supervised injectable programs — and monitor your labs to track whether you're actually seeing changes in the markers that matter.

The longevity space is moving fast. What's theoretical today may have trial data within 2–3 years. In the meantime, don't let biohacker enthusiasm outrun the evidence — but don't ignore legitimate science because it hasn't been rubber-stamped yet either.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content or provider selection.